GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Read renal action and limits
Local official-label summarySource retrieved 2026-11-07See the evidence for this drug3 sources available - open source summaries, references and comparisons

Atripla

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Atripla - product and source limitations

Check all three agents. The renal rules for tenofovir alafenamide products differ.

Before applying: Verify the current prescribing information for this presentation.

Also check: Atripla - product and source limitations

Official source

Atripla - labeled renal guidance

Renal action and limits

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet
Creatinine clearance (CrCl), mL/min; use the product-specific calculation

This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.

Action or finding
Below CrCl 50 mL/min, the fixed combination is not recommended. Its components cannot be adjusted individually in this tablet.
Limits and monitoring
Check all three agents. The renal rules for tenofovir alafenamide products differ.
Before use
Verify the current prescribing information for this presentation.

DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013 | Selected sections checked 2026-11-07. Independent clinical review pending.

Choose a product and source GlobalRPh RX passage HHS HIV guidelines panel / ClinicalInfo All evidence
Product / population
Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet
Renal measure
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source revision
DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Retrieved
2026-11-07 (not the revision date)
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Renal guidance: Renal impairment and fixed-dose limitations

Below CrCl 50 mL/min, the fixed combination is not recommended. Its components cannot be adjusted individually in this tablet. Check all three agents. The renal rules for tenofovir alafenamide products differ.

Source revision: DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Atripla - labeled renal guidance

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
GlobalRPh RX List

Atripla - selected RX renal passage

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference
Professional guidance

Atripla - HHS HIV guidelines panel / ClinicalInfo

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Adults or adolescents with HIV taking the efavirenz/emtricitabine/TDF fixed-dose tablet.

Renal method: Adult CrCl in mL/min; panel has a separate hemodialysis entry.
Retrieved: 2026-11-07

Read local renal resultOpen this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Atripla - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.
Professional source

Atripla - HHS HIV guidelines panel / ClinicalInfo

Adults or adolescents with HIV taking the efavirenz/emtricitabine/TDF fixed-dose tablet.

Method: Adult CrCl in mL/min; panel has a separate hemodialysis entry.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeAtripla - labeled renal guidanceAtripla - selected RX renal passageAtripla - HHS HIV guidelines panel / ClinicalInfo
Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9

Product identity and scope

Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

RDM73-atripla-identity-1 · Source section: Product identity and scopeRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

Atripla - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Renal method: Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date: DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: Renal impairment and fixed-dose limitations

Below CrCl 50 mL/min, the fixed combination is not recommended. Its components cannot be adjusted individually in this tablet. Check all three agents. The renal rules for tenofovir alafenamide products differ.

RDM73-atripla-official-1 · Source locator: Renal guidance: Renal impairment and fixed-dose limitations

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9
Retrieved
2026-11-07
Renal-function method
Creatinine clearance (CrCl), mL/min; use the product-specific calculation
Source date/version
DailyMed SPL version 3, effective 2013-05-03; posted May 06, 2013
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
840ca88d6bfbc10c7d8d582da7cf3cc5a1caaa55fb1e50f87aee4d779e7198a8
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

Atripla - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla), fixed-dose oral tablet

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror uses a CrCl threshold of 50 mL/min for the fixed tablet.

RDM73-atripla-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/atripla-drug/
Retrieved
2026-11-07
Renal-function method
Use the renal measure explicitly present in the RX passage.
Source date/version
Mirror revision not established in the reviewed passage.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
caeb653215e7df7124bd77301bbfc3c1c2fd0bf60258380f89445545c9f335f6
Separate professional-source layer

University and professional protocols

Professional

Atripla - HHS HIV guidelines panel / ClinicalInfo

Open original reference

Open / share this exact local source

HHS HIV guidelines panel / ClinicalInfo · Adults or adolescents with HIV taking the efavirenz/emtricitabine/TDF fixed-dose tablet.

Renal method: Adult CrCl in mL/min; panel has a separate hemodialysis entry.
Source date: Online guidance checked 2026-11-07; section revision not established.
Retrieved: 2026-11-07

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected renal passages reviewed; independent clinician adjudication pending.

Appendix B, efavirenz/emtricitabine/TDF row

The panel advises avoiding TDF when possible below CrCl 60 mL/min. This efavirenz/emtricitabine/TDF fixed combination is not recommended below 50 mL/min or on HD. The ingredient-level TDF interval must not be applied to the fixed tablet.

RDM73-atripla-professional-1 · Source locator: Appendix B, efavirenz/emtricitabine/TDF row

Source identity and provenance
Source family
professional_guideline
Source
https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/drug-characteristics-tables-renal-hepatic-insufficiency-full
Retrieved
2026-11-07
Renal-function method
Adult CrCl in mL/min; panel has a separate hemodialysis entry.
Source date/version
Online guidance checked 2026-11-07; section revision not established.
Hash meaning
SHA-256 of the local selected-source summary
Local summary SHA-256
5d1555563e492dc07f1894ebc8125020f99f81054fe8dc6ffc1b54e2706fd7ec

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2096a07e-8601-4bdc-ba5a-338a40cd02e9
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
0d399694d818dd78bf63632f96ab39ae13765f73e983c197fa443403d30b7de6
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top